Observational studyMycoses2026
Clinical Utility of the Paed-EQUAL Candida Score in Paediatric Candidemia: A Real-World Cohort Study.
Observational study in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal candidemia over seven years: Epidemiological trends, risk factors, and outcome associations with Paed-EQUAL Candida score adherence.European journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Paed-EQUAL Candida Score was developed to assess adherence to guideline-recommended management in paediatric candidemia; however, its clinical utility in predicting outcomes remains unclear, particularly in paediatric populations where validation data are scarce.
methodsWe conducted a retrospective observational study including paediatric patients diagnosed with candidemia at a tertiary-care centre between 2014 and 2024. The Paed-EQUAL Candida Score was calculated for each patient, and its association with 30-day and 90-day mortality was evaluated using ROC curve analysis, and optimal cut-off values were explored.
resultsA total of 127 paediatric patients with candidemia were included, of whom 17 (13.4%) died within 30 days and 27 (21.3%) within 90 days. Central venous catheter removal was significantly associated with improved survival at both 30 days (76.4% vs. 35.3%, p = 0.001) and 90 days (77% vs. 48.1%, p = 0.007). Higher adherence to Paed-EQUAL Candida Score components was observed among survivors, with significantly higher median scores in survivors compared to non-survivors at 30 days (17 [IQR 14-18] vs. 14 [12-16], p = 0.026). However, the score indicated modest discriminative ability for predicting mortality, with an AUC of 0.667 (95% CI 0.577-0.748) for 30-day mortality and no significant predictive value for 90-day mortality (AUC 0.594, 95% CI 0.503-0.680).
conclusionThe Paed-EQUAL Candida Score demonstrated limited prognostic performance in paediatric candidemia and may have constraints in its ability to support clinical decision-making, particularly given its modest discriminative capacity. While it remains a potentially useful tool for assessing adherence to quality-of-care measures, further refinement or development of paediatric-specific and outcome-oriented scoring systems may be needed to improve risk stratification and prediction of clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.